Full metadata record
DC FieldValueLanguage
dc.creatorKaufman, J.L. (Jonathan L.)-
dc.creatorDimopoulos, M.A. (Meletios A.)-
dc.creatorWhite, D.J. (Darrell J.)-
dc.creatorBenboubker, L. (Lotfi)-
dc.creatorCook, G. (Gordon)-
dc.creatorLeiba, M. (Merav)-
dc.creatorMorton, J. (James)-
dc.creatorTakezako, N. (Naoki)-
dc.creatorKim, K. (Kihyun)-
dc.creatorMoreau, P. (Philippe)-
dc.creatorSutherland, H.J. (Heather J.)-
dc.creatorMagen, H. (Hila)-
dc.creatorIida, S. (Shinsuke)-
dc.creatorKim, J.S. (Jin Sheok)-
dc.creatorPrince, H.M. (H. Miles)-
dc.creatorCochrane, T. (Tara)-
dc.creatorOriol, A. (Albert)-
dc.creatorO’Rourke, L. (Lisa)-
dc.creatorTrivedi, S. (Sonali)-
dc.creatorCasneuf, T. (Tineke)-
dc.creatorKrevvata, M. (Maria)-
dc.creatorUkropec, J. (Jon)-
dc.creatorKobos, R. (Rachel)-
dc.creatorAvet-Loiseau, H. (Herve)-
dc.creatorUsmani, S.Z. (Saad Z.)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.identifier.citationKaufman, J.L. (Jonathan L.); Dimopoulos, M.A. (Meletios A.); White, D.J. (Darrell J.); et al. "Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX". Blood Cancer Journal. 10 (111), 2020,es
dc.description.abstractHigh cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10–5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk.-
dc.description.sponsorshipThis study was sponsored by Janssen Research & Development, LLC. The authors would like to thank the patients who participated in this study and their families, as well as the study co-investigators, research nurses, and coordinators at each of the clinical sites. The authors thank Nikki DeAngelis, PhD, of Janssen Research & Development, LLC for her insights on the study. Medical writing and editorial support were provided by Kristin Runkle, PhD, of MedErgy, and were funded by Janssen Global Services, LLC.es_ES
dc.titleDaratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXes_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.es_ES
dc.editorial.noteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliationses_ES
dadun.citation.publicationNameBlood Cancer Journales_ES

Files in This Item:
667.65 kB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.